comparemela.com

Page 2 - Investors Media News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bicycle Therapeutics plc: Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium

Company to Host Conference Call on February 14 at 8:00 a.m. ET - Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on

United statesUnited kingdomSan franciscoDavid borahGustave roussyCapucine baldiniSarah suttonYale school of medicineCapital markets corporate communicationsAmerican society for clinical oncologyCompany to host conference call onHost conference callClinical oncologyCancers symposiumMedical oncologistDaniel petrylak

Bicycle Therapeutics plc: Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

United kingdomDavid borahSarah suttonPiper sandlerBicycle therapeuticsLondon healthcare conferenceAnnual healthcare conferenceInvestors mediaBicycle toxin conjugateCancer research united kingdom centreCapital markets investor relations

Bicycle Therapeutics plc: Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors

Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete response) and 67%, respectively

United kingdomUnited statesDavid borahDominic smethurstSarah suttonKevin leeExchange commissionChief medical officerBicycle toxin conjugateChief executive officerResponse evaluation criteriaSolid tumorsBicycle therapeuticsInvestors mediaCancer research united kingdom centrePrivate securities litigation reform act

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based

United statesUnited kingdomDavid borahMeredith mckeanMary jane elliottAmerican association for cancer research annual meetingSarah cannon research institute at tennessee oncologyCompany to host conference call onConsilium strategic communicationsHost conference callCancer research annual meetingNew orleansNovel bi cyclic peptideAdvanced malignancies associatedSarah cannon research instituteTennessee oncology

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed and an 80% disease control rate in 5 EphA2-positive ovarian cancer

United statesUnited kingdomMedimmune ephDavid borahDominic smethurstMary jane elliottKevin leeExchange commissionConsilium strategic communicationsBicycle toxin conjugatesChief medical officerChief executive officerResponse evaluation criteriaSolid tumorsInvestors mediaBicycle toxin conjugate

vimarsana © 2020. All Rights Reserved.